FYR
FYR is revolutionizing the ability to dynamically observe disease and treatment response to produce better biomarkers, better trials, better drugs, and better outcomes. FYR’s EV-Omics (EVO) platform leverages its proprietary technology, SPARCsTM, to enrich extracellular vesicles from diseased cells and reveal a treasure trove of proteins and nucleic acids. The unparalleled view provided by FYR’s multiomics approach can transform personalized patient care, from screening through therapy selection and monitoring. For more, visit fyr.bio.
